Genomic Vision SA

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, BIM.PA has a market cap of 14.8B. Regarding current trading prices, GV.PA is priced at €0.00, while BIM.PA trades at €125.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas BIM.PA's P/E ratio is 34.42. In terms of profitability, GV.PA's ROE is -7.61%, compared to BIM.PA's ROE of +0.11%. Regarding short-term risk, GV.PA is more volatile compared to BIM.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check BIM.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, ERF.PA has a market cap of 12.2B. Regarding current trading prices, GV.PA is priced at €0.00, while ERF.PA trades at €68.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas ERF.PA's P/E ratio is 30.29. In terms of profitability, GV.PA's ROE is -7.61%, compared to ERF.PA's ROE of +0.05%. Regarding short-term risk, GV.PA is more volatile compared to ERF.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check ERF.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, LBIRD.PA has a market cap of 434.7M. Regarding current trading prices, GV.PA is priced at €0.00, while LBIRD.PA trades at €19.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas LBIRD.PA's P/E ratio is 75.96. In terms of profitability, GV.PA's ROE is -7.61%, compared to LBIRD.PA's ROE of +0.03%. Regarding short-term risk, GV.PA is more volatile compared to LBIRD.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check LBIRD.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, ALECR.PA has a market cap of 90.8M. Regarding current trading prices, GV.PA is priced at €0.00, while ALECR.PA trades at €18,000.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas ALECR.PA's P/E ratio is 12.69. In terms of profitability, GV.PA's ROE is -7.61%, compared to ALECR.PA's ROE of +0.10%. Regarding short-term risk, GV.PA is more volatile compared to ALECR.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check ALECR.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, MDXH.BR has a market cap of 85.6M. Regarding current trading prices, GV.PA is priced at €0.00, while MDXH.BR trades at €3.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas MDXH.BR's P/E ratio is -1.58. In terms of profitability, GV.PA's ROE is -7.61%, compared to MDXH.BR's ROE of -1.79%. Regarding short-term risk, GV.PA is more volatile compared to MDXH.BR. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check MDXH.BR's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, BCART.BR has a market cap of 27.2M. Regarding current trading prices, GV.PA is priced at €0.00, while BCART.BR trades at €0.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas BCART.BR's P/E ratio is -0.32. In terms of profitability, GV.PA's ROE is -7.61%, compared to BCART.BR's ROE of +2.04%. Regarding short-term risk, GV.PA is more volatile compared to BCART.BR. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check BCART.BR's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, ALBIO.PA has a market cap of 22.2M. Regarding current trading prices, GV.PA is priced at €0.00, while ALBIO.PA trades at €1.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas ALBIO.PA's P/E ratio is -0.37. In terms of profitability, GV.PA's ROE is -7.61%, compared to ALBIO.PA's ROE of -0.38%. Regarding short-term risk, GV.PA is more volatile compared to ALBIO.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check ALBIO.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, ALPRE.PA has a market cap of 12.9M. Regarding current trading prices, GV.PA is priced at €0.00, while ALPRE.PA trades at €3.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas ALPRE.PA's P/E ratio is -2.90. In terms of profitability, GV.PA's ROE is -7.61%, compared to ALPRE.PA's ROE of +1.10%. Regarding short-term risk, GV.PA is more volatile compared to ALPRE.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check ALPRE.PA's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, EEP.MC has a market cap of 6.3M. Regarding current trading prices, GV.PA is priced at €0.00, while EEP.MC trades at €0.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas EEP.MC's P/E ratio is -54.00. In terms of profitability, GV.PA's ROE is -7.61%, compared to EEP.MC's ROE of N/A. Regarding short-term risk, GV.PA is less volatile compared to EEP.MC. This indicates potentially lower risk in terms of short-term price fluctuations for GV.PA.Check EEP.MC's competition here

GV.PA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, GV.PA stands at 693.2K. In comparison, MLAHC.PA has a market cap of 5.4M. Regarding current trading prices, GV.PA is priced at €0.00, while MLAHC.PA trades at €0.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

GV.PA currently has a P/E ratio of -0.02, whereas MLAHC.PA's P/E ratio is -10.00. In terms of profitability, GV.PA's ROE is -7.61%, compared to MLAHC.PA's ROE of N/A. Regarding short-term risk, GV.PA is more volatile compared to MLAHC.PA. This indicates potentially higher risk in terms of short-term price fluctuations for GV.PA.Check MLAHC.PA's competition here